Atrioventricular Septal Defect (AVSD): A Comprehensive Disease Characteristics Report

Disease: Atrioventricular Septal Defect (AVSD) — also atrioventricular canal defect / endocardial cushion defect MONDO ID: MONDO:0859565 Category: Congenital heart defect (endocardial cushion / atrioventricular canal defect) Evidence base: 92 primary papers reviewed; 22 findings recorded; 5 hypotheses (all supported). Information derived from aggregated disease-level resources plus clinical cohorts, model-organism studies, and in vitro/computational work.

Summary

Atrioventricular septal defect (AVSD) is a congenital cardiac malformation defined by a common atrioventricular (AV) junction resulting from deficient development of the atrioventricular septum. Anatomically it comprises an ostium primum atrial communication and/or an inlet ventricular septal defect together with an abnormal AV valve — either a single common valve (complete AVSD) or two valve orifices with a cleft left AV valve (partial AVSD). The malformation arises from failed atrioventricular-canal endocardial cushion development, specifically defective endothelial-to-mesenchymal transition (EndoMT) governed by TGF-β, BMP, Notch and Wnt/β-catenin signaling (PMID: 29549339). AVSD represents roughly 4–7% of all congenital cardiac malformations (PMID: 37612667).

AVSD has the tightest link of any congenital heart defect to trisomy 21 (Down syndrome): AVSD is the most common heart defect in Down syndrome (~44%), and roughly half of all AVSD cases occur in the context of Down syndrome (PMID: 39104126; PMID: 37667895). Beyond trisomy 21, the genetic architecture is heterogeneous and often oligogenic, involving cardiac transcription factors and developmental signaling genes (CRELD1, GATA4/6, NR2F2, NFATC1, GDF1, NOTCH1, BMPR1A, HEY2) plus rare copy-number variants, converging on the CRELD1–calcineurin/NFATc1–VEGF axis (PMID: 15096951; PMID: 30007050; PMID: 24697899). On chromosome 21, gene-dosage effects (cooperative DSCAM+COL6A2 overexpression; HMGN1-driven myocardial reprogramming) contribute to the trisomy-21 phenotype (PMID: 22072978; PMID: 41125893). Maternal pregestational diabetes is a strong modifiable environmental risk factor (adjusted prevalence ratio ~6.7 for non-syndromic AVSD), while folate-rich diet is protective (PMID: 23061687; PMID: 32092068).

Hemodynamically, the defect produces a large left-to-right shunt with common-valve regurgitation, causing infantile congestive heart failure and, if left unrepaired, irreversible pulmonary vascular obstructive disease (Eisenmenger physiology) (PMID: 1943197; PMID: 10812553). Diagnosis rests on echocardiography (AVSD is the most common fetal cardiac diagnosis, with 90–100% fetal-echo sensitivity and the highest genetic-testing yield of any CHD subtype) (PMID: 37240614; PMID: 34196822; PMID: 33142350). Treatment is surgical repair in infancy (single-patch, modified single-patch, or double-patch), with excellent modern long-term survival (~80–88% at 10–25 years) and left AV valve regurgitation as the principal residual problem and reoperation driver (PMID: 40154545; PMID: 34002204).

This report synthesizes 22 confirmed findings from 10 iterations across 92 reviewed papers, organized against the 15-section disease-characteristics template.

1. Disease Information

AVSD (atrioventricular septal defect) is a structural congenital heart malformation characterized by a common atrioventricular junction with deficient atrioventricular septation. The core anatomic lesion is an ostium primum atrial septal defect and/or an inlet ventricular septal defect with an abnormal common or cleft atrioventricular valve (PMID: 8347012). Forms range from partial/incomplete (primum ASD + cleft left AV valve, two valve orifices) through transitional to complete (single common AV valve, combined atrial and ventricular communications).

Key identifiers: - MONDO: MONDO:0859565 - Common synonyms/alternative names: atrioventricular canal defect, common atrioventricular canal (CAVC), endocardial cushion defect, AV canal defect, persistent common atrioventricular canal - ICD-10: Q21.2 (atrioventricular septal defect); MeSH: "Heart Septal Defects" / "Endocardial Cushion Defects" - Additional clinical descriptors: complete AVSD (CAVSD), partial AVSD (pAVSD), transitional AVSD

Source of information: This report draws primarily on aggregated disease-level resources — surgical/echocardiographic cohorts, population-based birth-defect registries (Texas Birth Defects Registry, National Birth Defects Prevention Study, US National Inpatient Sample), genetic studies, and model-organism experiments — rather than individual EHR records.

2. Etiology

Disease Causal Factors

AVSD is a multifactorial, genetically heterogeneous malformation. The unifying developmental cause is failed fusion/development of the atrioventricular-canal endocardial cushions (see Section 6). Causal contributors span:

• Chromosomal: trisomy 21 (the single largest contributor), plus other aneuploidies (trisomy 18, trisomy 13) and specific deletions (e.g., 3p25–pter / 3p- syndrome, in which AVSD occurs in ~one-third of patients; PMID: 19760623).
• Single-gene / oligogenic: CRELD1, GATA4, GATA6, NR2F2, NKX2-5, TBX5, BMP4, NFATC1, GDF1, NOTCH1, BMPR1A, HEY2 (see Section 4).
• Environmental: maternal pregestational and gestational diabetes, maternal obesity, poor periconceptional diet.

CRELD1 was the first identified non-syndromic AVSD susceptibility gene; critically, "Mutation of CRELD1 increases susceptibility to AVSD but is not alone sufficient to cause the defect, indicating that AVSD is multigenic" (PMID: 15096951).

Risk Factors

Genetic risk factors — trisomy 21 (dominant), CRELD1 missense variants (~5–10% of simplex AVSD carry a CRELD1 missense mutation; PMID: 25328912), and rare damaging variants across ~112 biologically relevant genes enriched in AVSD probands (OR 1.52, 95% CI 1.35–1.71, P = 4.8×10⁻¹¹; PMID: 25996639).

Environmental risk factors — maternal pregestational diabetes is the strongest (adjusted prevalence ratio [aPR] 6.74, 95% CI 3.67–12.37 for non-syndromic complete AV canal), followed by gestational diabetes (aPR 1.69) and obesity (aPR 1.69) (PMID: 23061687). Advanced maternal age (via aneuploidy risk), low maternal education, and poor diet are additional contributors (PMID: 32092068).

Protective Factors

Environmental protective factors — frequent consumption of folate-rich fruits was protective for CHD (adjusted OR 0.64, 95% CI 0.47–0.89), and consistent periconceptional folic-acid supplementation trended protective for cardiac-inclusive anomalies (aOR 0.5, 95% CI 0.3–1.0) (PMID: 32092068; PMID: 33179873). Genetic protective factors specific to AVSD are not well established.

Gene–Environment Interactions

The clearest example is a genetic-threshold/modifier model: crossing loss-of-function alleles of Creld1 or Hey2 onto the trisomic Ts65Dn background "caused a significant increase in the frequency of CHD," demonstrating that additional genetic perturbations push a dosage-sensitized background across a defect threshold (PMID: 22523272). On the environmental side, gestational diabetes and obesity show additive interaction for AVSD risk (RERI 1.1, 95% CI −0.1 to 2.3; PMID: 33876578).

3. Phenotypes

Phenotype characteristics: Symptoms typically begin in the first weeks-to-months of life (mean symptom onset ~50 ± 75 days in complete AVSD; PMID: 9532811). Severity ranges from mild (partial AVSD, sometimes asymptomatic into adulthood) to severe (complete AVSD with heart failure). Progression is progressive if unrepaired, driven by pulmonary overcirculation. A key phenotypic contrast: "There seems to be a pulmonary vascular hyperreactivity predominance in Down's children and cardiac insufficiency signs in the normal genetic group" (PMID: 9532811) — non-Down patients had more severe AV valve morphologic lesions (38% vs 8%).

Quality of life impact: After repair, long-term QoL is favorable — self- or caregiver-reported QoL was "excellent or good in 81%" of patients up to 40 years after single-patch complete AVSD repair (PMID: 34953470).

4. Genetic / Molecular Information

Causal and Susceptibility Genes

The genetic etiology remains unknown in ~40% of cases (PMID: 25996639). Exome sequencing found significant enrichment of rare variants in AVSD vs tetralogy of Fallot (OR 2.25, P = 2.2×10⁻¹⁶), indicating disease-specific genetic burden. Diagnostic yield of exome sequencing in Southern African CHD was 7.9% (PMID: 42037320).

Variant Classification, Type, Origin, and Consequences

• Classification (ACMG/AMP): ranges from pathogenic/likely pathogenic (aneuploidy, syndromic-gene LOF) to VUS (many CRELD1/GATA6 missense variants).
• Variant type: missense (CRELD1, NFATC1, GATA6, BMPR1A), plus structural/copy-number variants; aneuploidy (trisomy 21) is the dominant chromosomal class.
• Origin: predominantly germline; somatic origin is not a feature of AVSD.
• Functional consequences: loss of function (NFATC1 — "defective nuclear translocation and decreased transcriptional transactivation activity"; PMID: 30007050), gain of function (GATA6 A178V increased transactivation), and dosage effects (chr21 genes).

Modifier Genes and Chromosomal Abnormalities

Modifiers: VEGFA interacts allelically with CRELD1 as a modifier of AVSD risk (PMID: 25328912); Creld1 and Hey2 modify trisomy-21 CHD frequency (PMID: 22523272). Chromosomal abnormalities: trisomy 21 predominates. Rare CNV burden in 150 AVSD cases concentrated on chromosomes 19, 22, 21, and 16 and nominated 20 candidate genes (PMID: 36816019). In 262 Chinese complete AV canal cases, potentially-causative CNVs were found in 16.4%, of which 90.7% carried 21q11.2–q22.3 duplication (trisomy 21) (PMID: 34627233).

Epigenetic information: The chr21 chromatin architectural protein HMGN1 drives trisomy-21 heart defects via myocardial transcriptional/chromatin reprogramming (PMID: 41125893).

Suggested ontology terms: HGNC CRELD1, GATA4, GATA6, NFATC1, NOTCH1, BMPR1A, HMGN1; CHEBI:calcium (calcium-binding EGF domain).

5. Environmental Information

Environmental factors: Maternal metabolic environment dominates. Pregestational diabetes is the strongest single non-genetic factor: "Significant associations were observed between non-syndromic CAVC in offspring and maternal pregestational diabetes (aPR 6.74; 95% CI 3.67, 12.37), gestational diabetes (aPR 1.69) and obesity (aPR 1.69)" (PMID: 23061687). Pregestational diabetes was strongly associated with most birth defects (OR 2.0–75.9) in the National Birth Defects Prevention Study (PMID: 33876578).

Lifestyle factors: Poor maternal diet low in fruit/vegetables increased CHD risk (aOR 1.56); maternal smoking (~2-fold) and overweight/obesity (aOR 1.8) were risk factors for cardiac-inclusive anomalies (PMID: 32092068; PMID: 33179873). Folate-rich diet is protective (see Section 2).

Infectious agents: Not applicable — AVSD is a developmental malformation, not an infectious disease.

6. Mechanism / Pathophysiology

The Central Developmental Mechanism: Failed Endocardial Cushion EndoMT

The AV septum and valves derive from endocardial cushions, formed when endocardial cells of the atrioventricular canal (AVC) undergo endothelial-to-mesenchymal transition (EndoMT/EMT), delaminate, and invade the cardiac jelly (extracellular matrix). "Atrioventricular septal defects often result from impaired endocardial cushion development. Endothelial-to-mesenchymal transition (EndoMT) is a critical event in endocardial cushion development that initiates in the atrioventricular canal (AVC)" (PMID: 29549339).

Molecular pathways governing EndoMT:

• TGF-β signaling induces EndoMT; MBNL1 negatively regulates TGF-β/EMT, and Mbnl1-null mice show precocious EMT, later valve dysmorphia, and ostium secundum septal defects (PMID: 26472242).
• BMP signaling — "Bone morphogenetic protein (BMP) signalling plays a key role in regulating the development of the atrioventricular (AV) septum and valves"; Sema6D acts downstream of BMP to promote AV cushion development (PMID: 28172500).
• Notch signaling gates the process — endocardial Mib1–Dll4–Notch1 drives EMT and Jag1–Notch1 restrains post-EMT proliferation; "Mice lacking endocardial Jag1, Notch1, or RBPJ displayed enlarged valve cusps, bicuspid aortic valve, and septal defects" (PMID: 27056911). Manic Fringe (MFNG) promotes Notch-mediated EndMT; "Aberrant EndMT is a primary cause of congenital valvular malformations" (PMID: 39528804).
• Wnt/β-catenin signaling — "Disruption of these Wnt/β-catenin signaling roles that enable developmental transitions during valvulogenesis could account for common congenital valve defects" (PMID: 26893350).
• NADPH oxidase NOX2-derived ROS is critical to EndoMT and heart development (PMID: 32655758).

The CRELD1 → Calcineurin/NFATc1 → VEGF Axis

A specific convergent module operates in AV canal endocardium: "Multiple lines of evidence support a role of calcineurin/NFAT signaling in AVSD, and mutations in CRELD1, a protein functioning as a regulator of calcineurin/NFAT signaling have been reported" (PMID: 30007050). Murine work established the causal chain: "Creld1 function is required for the VEGF-dependent proliferation of endocardial cells by promoting the expression of NFATc1 target-genes" (PMID: 24697899); Creld1 promotes NFATc1 dephosphorylation and nuclear translocation via a complex with the calcineurin regulatory subunit CnB at the endoplasmic reticulum. Human pre-valvular endocardial cells from pluripotent stem cells recapitulate BMP2-responsive AVC EndoMT in vitro (PMID: 31028265).

Trisomy 21 Gene-Dosage Mechanisms

• Cooperative overexpression: DSCAM and COL6A2 (both chr21) are "the most strongly interacting pair of genes"; co-overexpression in mouse heart caused "≈50% mortality and severe physiological and morphological defects, including atrial septal defects and cardiac hypertrophy," whereas single-gene overexpression did not (PMID: 22072978).
• HMGN1-mediated reprogramming: the chromatin architectural gene HMGN1 drives myocardial transcriptional reprogramming underlying trisomy-21 heart defects (PMID: 41125893).

Hemodynamic Pathophysiology (Downstream Clinical Mechanism)

Once the structural defect exists, a large left-to-right shunt develops. "With increasing shunt ratio the pulmonary perfusion raised (r = 0.84), but the systemic output dropped significantly (r = -0.77)" (PMID: 10812553). Untreated, "The natural history of patients with complete atrioventricular canal defect is one of unrelenting development of pulmonary vascular obstructive disease" (PMID: 1943197), culminating in Eisenmenger physiology.

Causal Chain Diagram

UPSTREAM (developmental)                          DOWNSTREAM (clinical)
─────────────────────────────────────────────────────────────────────────
Trisomy 21 dosage (DSCAM+COL6A2, HMGN1)
   │
Genetic variants (CRELD1, NFATC1, GATA4/6,        Structural defect
   NOTCH1, BMPR1A, GDF1, HEY2)                     (common AV junction,
   │          +                                    primum ASD ± inlet VSD,
Maternal environment (diabetes, obesity)           common/cleft AV valve)
   │                                                      │
   ▼                                                      ▼
Impaired AVC endocardial cushion EndoMT           Large left-to-right shunt
(TGF-β / BMP / Notch / Wnt / NOX2-ROS;              + AV valve regurgitation
 CRELD1→calcineurin/NFATc1→VEGF)                          │
   │                                                      ▼
   ▼                                              Pulmonary overcirculation →
Failed AV septation & valve formation             CHF (infancy) → pulmonary
                                                   vascular obstructive disease
                                                   → Eisenmenger (if untreated)

GO terms: GO:0003198 (EMT involved in endocardial cushion formation), GO:0003181 (atrioventricular valve morphogenesis), GO:0060411 (cardiac septum morphogenesis). CL terms: CL:0002350 (endocardial cell), CL:0000057 (fibroblast/valve interstitial cell), CL:0000746 (cardiac muscle cell).

7. Anatomical Structures Affected

Organ level: The heart is the primary affected organ, specifically the atrioventricular septum and atrioventricular valves. Secondary organ involvement includes the lungs/pulmonary vasculature (pulmonary vascular obstructive disease) and, via heart failure, the liver (hepatomegaly). The cardiovascular and respiratory systems are principally involved.

Anatomical detail: AVSD is defined by a common atrioventricular junction with deficient AV septation. The Rastelli classification categorizes the anterior (superior) bridging leaflet of the common valve into types A, B, and C, guiding surgical strategy; interventricular communication under the posterior leaflet is surgically decisive (PMID: 8347012). In Down syndrome, characteristic outlet-septum anterior malalignment occurs — "Outlet extension of the ventricular component of the defect with outlet septum anterior malalignment was found in 90.6% of Down vs 12.8% of non-Down patients" (PMID: 39892564) — and Rastelli type A morphology is an independent risk factor for pulmonary vascular disease in Down syndrome (PMID: 10946038).

Tissue and cell level: Affected tissues include the endocardial cushion mesenchyme, AV valve leaflet connective tissue, and adjacent myocardium. Key cell populations: endocardial (endothelial) cells undergoing EndoMT and their mesenchymal/valve interstitial cell derivatives; cardiomyocytes in trisomy-21 reprogramming.

Subcellular level: GO cellular components implicated: nucleus (NFATc1 translocation; HMGN1 chromatin), endoplasmic reticulum (Creld1–calcineurin complex), and extracellular matrix / cardiac jelly.

Localization: Central heart — the atrioventricular canal region; the lesion is midline/central rather than lateralized. UBERON terms: UBERON:0002087 (atrioventricular region), UBERON:0002078/0002079 (right/left cardiac atrium), UBERON:0003504 (cardiac atrioventricular valve), UBERON:0002094 (interatrial septum), UBERON:0002099 (interventricular septum), UBERON:0002348 (endocardium).

8. Temporal Development

Onset: Congenital — the structural defect forms during embryonic cardiac septation (weeks 4–8 of human development). Clinical symptoms emerge in the neonatal-to-infantile period, with mean symptom onset ~50 ± 75 days in complete AVSD (PMID: 9532811). Onset pattern is insidious-to-subacute as pulmonary vascular resistance falls postnatally and the left-to-right shunt increases.

Progression: Without repair, the course is progressive — pulmonary overcirculation → congestive heart failure → pulmonary vascular obstructive disease. "The natural history ... is one of unrelenting development of pulmonary vascular obstructive disease" (PMID: 1943197). Partial AVSD may progress more slowly and occasionally present in adulthood.

Critical periods / windows of intervention: Complete AVSD is repaired at ~3–6 months of age to preempt irreversible pulmonary vascular disease. Late repair (≥6 months) can yield comparable outcomes in resource-limited settings (PMID: 42079968), but advanced pulmonary vascular disease may already be established at operation (PMID: 1943197). Remission is treatment-induced (surgical repair); spontaneous resolution does not occur for complete AVSD. Disease is lifelong — repaired patients require ongoing surveillance for LAVV regurgitation, LVOT obstruction, and arrhythmias.

9. Inheritance and Population

Epidemiology: AVSD accounts for ~4–7% of all congenital cardiac malformations (PMID: 37612667) and ~2.6% of pediatric CHD hospitalizations; US prevalence increased over 2016–2020 (PMID: 38277408). It is the most common CHD in Down syndrome (44.4%; PMID: 39104126) and, conversely, ~54.7% of AVSD cases occur with Down syndrome (PMID: 37667895).

Inheritance pattern: Predominantly multifactorial/polygenic with strong chromosomal (trisomy 21) contribution. Non-syndromic familial cases show oligogenic inheritance (e.g., co-occurring GDF1+NOTCH1; BMPR1A co-segregating with a chr1 linkage region) rather than a single Mendelian gene (PMID: 38975735; PMID: 30814609). Penetrance is incomplete and expressivity is variable — consistent with CRELD1 being susceptibility rather than sufficient (PMID: 15096951). Genetic anticipation and repeat-expansion mechanisms are not applicable.

Population demographics: - Down syndrome is the dominant demographic association. - Sex ratio: slight female predominance — girl:boy ratio 1.17:1 in a population-based Bohemian study (PMID: 7997413); in Chinese CAVC-with-DS cases the female:male ratio was 1.6:1.0 (PMID: 34627233). - Age distribution: presents in infancy; a growing adult congenital population exists (partial AVSD, repaired complete AVSD). - Consanguinity and founder effects are relevant for rare recessive/syndromic forms but not central to AVSD epidemiology.

10. Diagnostics

Echocardiography is the gold standard — both fetal and postnatal. The diagnostic plane is the four-chamber view demonstrating a common AV junction, common AV valve, and the ostium primum and inlet communications: "the four-chamber views ... showed the atrioventricular septal defect and a common AV valve" (PMID: 36766561).

• Prenatal detection: high — antenatal diagnosis of complete AVSD ranges 57–92% (PMID: 27981284); increased detection has made AVSD "the most common fetal cardiac diagnosis" (PMID: 34196822). Expert fetal echo shows sensitivity 90–100%, specificity/NPV 97–100%, PPV 85–100%, with Cohen's kappa >0.9 vs postnatal MRI (PMID: 37240614).
• AI-assisted detection: the atrial-to-ventricular length ratio (AVLR) via CNN landmark detection is greater in AVSD than controls (P < 0.0001, AUC up to 0.992; PMID: 38323184); FINE/STIC 4D identified the common AV valve in 100% of four-chamber volumes with autopsy confirmation (PMID: 36766561).
• ECG: classically shows a superior/leftward ("northwest") QRS axis with AV conduction delay.
• Cardiac MRI/CT and cardiac catheterization (for pulmonary vascular resistance assessment) are adjuncts.

Genetic testing is integral given the aneuploidy link. Among unselected CHD fetuses, positive genetic diagnosis was highest for AVSD at 36.8% (chromosomal microarray detecting aneuploidy/pathogenic CNV in 16.7% overall; exome sequencing adding 6.7%; PMID: 33142350). Recommended workup: karyotype/chromosomal microarray (CMA) first-line (to detect trisomy 21 and pathogenic CNVs), with exome sequencing for non-isolated/syndromic or CMA-negative cases; MLPA CHD panels (GATA4, NKX2-5, TBX5, BMP4, CRELD1, 22q11.2) offer a cheaper first-tier screen (PMID: 29952356).

Clinical criteria & differential diagnosis: Diagnosis is anatomic (echo-based). Differentials include isolated ostium primum/secundum ASD, isolated inlet VSD, common atrium (near-complete absence of interatrial septum; PMID: 34993374), and heterotaxy-associated AVSD (AVSD is the most common cardiac anomaly in atrial isomerism; PMID: 28603940).

Screening: Because ~half of children with Down syndrome have CHD (most commonly AVSD), echocardiographic screening of all newborns/infants with Down syndrome is standard, though access barriers limit it in resource-poor settings (PMID: 41877065).

11. Outcome / Prognosis

Survival after repair is excellent and has improved across surgical eras.

Morbidity / disease course: The dominant late complication is left AV valve (LAVV) regurgitation, the principal reoperation driver, followed by LVOT obstruction (PMID: 41971883; PMID: 40208292). AVSD carries among the highest long-term arrhythmia risk of all CHDs (advanced AV block, atrial flutter/fibrillation; overall CHD arrhythmia HR 16.4, 95% CI 14.4–18.7; PMID: 39233212). Pulmonary hypertension is a key complication, more frequent in Down syndrome (4.3% vs 2.8%, P < 0.001; PMID: 37667895).

Prognostic factors: prematurity and low birth weight (mortality), pulmonary hypertension, prior pulmonary artery banding, surgical era, non-Down status and moderate postoperative LAVV regurgitation (reoperation risk; PMID: 34002204). Interestingly, older age at repair and Down syndrome were associated with decreased LAVV reintervention risk (PMID: 40208292). A high postoperative leuko-glycemic index predicts prolonged mechanical ventilation and acute kidney injury in Down-syndrome infants (PMID: 41764019).

12. Treatment

Definitive treatment is surgical biventricular repair — closure of the atrial (ostium primum) and ventricular components and reconstruction of the left AV valve (including cleft closure). NCIT concept: cardiac surgical repair of septal defect.

Surgical techniques: - Classic single-patch, modified single-patch ("Australian"/Nunn technique), and two-patch (double-patch) repair. The Nunn-modified single-patch achieves >90% freedom from LAVV reoperation and >97% freedom from LVOT obstruction at 10–15 years (PMID: 41313357). - Complete AVSD is repaired in infancy (~3–6 months) to prevent irreversible pulmonary vascular disease. "Early intervention, in the first 6 months ... gives comparable acceptable results to later repair; Trisomy 21 was not found to be a risk factor for early intervention" (PMID: 34350818). The modified single-patch shortened bypass time (71 vs 99 min, P = 0.001), and adding posterior annuloplasty reduced postoperative LAVV regurgitation (2+ regurgitation 43% → 7%, P = 0.03). - Complete cleft closure inhibits significant postoperative LAVV regurgitation (OR 0.36, 95% CI 0.14–0.93; PMID: 39578279). Refractory cases require valve replacement.

Pharmacotherapy (bridging / supportive): Anti-heart-failure therapy — diuretics (furosemide, spironolactone), afterload reduction (ACE inhibitors/enalapril), digoxin — plus nutritional support. Vasodilators lower vascular resistance but can induce hypotension because systemic output does not rise (PMID: 10812553). Pulmonary artery banding is an occasional palliative bridge (but prior banding predicts later mortality; PMID: 34002204). For established pulmonary hypertension, calcium-channel blockers (nifedipine) and modern PH-targeted therapy are used (PMID: 2116616; PMID: 37794522).

Advanced/gene/cell therapies: Not applicable — no gene, RNA, or cell therapies exist for AVSD; treatment is structural/surgical.

Adult AVSD repair is safe with low early mortality but notable late arrhythmia and residual LAVV reoperation (PMID: 40936386).

13. Prevention

Primary prevention targets modifiable maternal risk factors: - Optimize maternal glycemic control before and during pregnancy (pregestational diabetes aPR ~6.7; PMID: 23061687). - Periconceptional folic acid / folate-rich diet — protective for CHD (aOR 0.64; PMID: 32092068); provider awareness of folate's cardiac benefits is low and warrants education (PMID: 41041190). - Weight management and smoking cessation.

Secondary prevention (early detection): - Prenatal screening via the four-chamber view at the mid-trimester anomaly scan; quality of imaging strongly affects detection (PMID: 31131945). - Prenatal detection of AVSD prompts karyotype/aneuploidy workup given the strong trisomy-21 association (PMID: 36766561). - Routine echocardiographic screening of all infants with Down syndrome (PMID: 41877065).

Tertiary prevention (complication prevention): timely surgical repair before irreversible pulmonary vascular disease; lifelong surveillance for LAVV regurgitation, LVOT obstruction, arrhythmias, and pulmonary hypertension.

Genetic counseling: For families with AVSD/CHD, counseling addresses recurrence risk, oligogenic/multifactorial inheritance, and prenatal diagnostic options (CMA, exome sequencing, fetal echocardiography). Immunization/public-health/infectious prevention: not applicable.

14. Other Species / Natural Disease

AVSD (atrioventricular canal defect) occurs naturally across mammals: "The defect has been described in human beings, dogs, cats, pigs, and horses," and a 2021 report added the first documented complete AV canal defect in a pet ferret (Mustela putorius furo) — a 4-year-old male with a loud systolic murmur, dyspnea, cardiomegaly, and pulmonary edema, echocardiographically showing a large ASD, AV valve dysplasia, and VSD, managed palliatively with furosemide, spironolactone, enalapril, and diltiazem (PMID: 33482816).

• Taxonomy / NCBI Taxon: Homo sapiens (9606), Canis lupus familiaris (9615), Felis catus (9685), Sus scrofa (9823), Equus caballus (9796), Mustela putorius furo (9669).
• Comparative biology: The same developmental program — endocardial cushion formation via EndoMT under TGF-β/BMP/Notch/Wnt control — operates across vertebrates, indicating strong evolutionary conservation of AV-canal development. Orthologous genes (Creld1, Nfatc1, Notch1, Gata4) are conserved across species.
• Veterinary relevance: AVSD/AV canal defect is a recognized congenital cardiac malformation in companion animals, typically presenting with murmur and congestive heart failure signs.
• Zoonotic potential: none (developmental malformation).

15. Model Organisms

Overall model interpretation: Single-gene KOs (Creld1, Notch pathway) faithfully model the mechanistic EndoMT/calcineurin-NFATc1 axis, while Down-syndrome trisomy models (Ts65Dn, Ts16, Tc1) only partially recapitulate the human balanced AVSD morphology — a key limitation. The DSCR1-rescue negative result and Creld1/Hey2 modifier crosses jointly support an oligogenic, dosage-threshold model (PMID: 15906378; PMID: 22523272). Resources: MGI, IMPC, ZFIN, Cellosaurus.

Mechanistic Model / Interpretation

AVSD is best understood as a convergent endpoint of failed atrioventricular-canal endocardial cushion development, reached by multiple upstream routes (chromosomal, oligogenic, environmental) that all impair endothelial-to-mesenchymal transition and its downstream valve/septum morphogenesis. The pathway logic:

Upstream perturbations              Convergent module                 Structural outcome
──────────────────────  ───────────────────────────────────  ──────────────────────────
Trisomy 21 dosage ──┐
CRELD1 / NFATC1 ─────┤    CRELD1→Calcineurin/NFATc1→VEGF        Deficient AV septation
GATA4/6, NOTCH1 ─────┼──► TGF-β / BMP / Notch / Wnt / NOX2 ──►  + abnormal common/cleft
BMPR1A, GDF1, HEY2 ──┤    driven endocardial EndoMT & valve     AV valve
Maternal diabetes ───┘    remodeling                            (Rastelli A/B/C)

Two features make AVSD distinctive among CHDs: (1) its unusually tight link to trisomy 21, explained by chr21 gene-dosage effects (DSCAM+COL6A2 cooperativity; HMGN1 chromatin reprogramming) acting on a threshold-sensitized cushion program; and (2) the fact that its major residual clinical problem (LAVV regurgitation) is a direct anatomic consequence of the abnormal common-valve leaflet architecture, which surgery can improve but not perfectly normalize.

Evidence Base — Key Literature

Consistency: Findings were highly consistent across human clinical cohorts, model organisms, and in vitro systems. No hypothesis was refuted; all 5 formal hypotheses (H001–H005) were supported.

Limitations and Knowledge Gaps

1. ~40% of non-syndromic AVSD lacks a molecular diagnosis (PMID: 25996639) — much of the oligogenic/polygenic architecture and regulatory (non-coding) contribution remains uncharacterized.
2. DS models imperfectly recapitulate human balanced AVSD morphology (PMID: 9231034); the precise chr21 gene(s) and dosage thresholds driving human AVSD are not fully resolved (HMGN1 and DSCAM+COL6A2 are leading but not sole candidates).
3. Environmental risk estimates derive largely from broad CHD studies, not AVSD-specific cohorts; folate/diabetes effect sizes for AVSD alone are less precise.
4. No molecular/epigenetic biomarker exists for prenatal risk stratification or postoperative LAVV-regurgitation prediction; diagnosis remains imaging-based.
5. Limited data on adult natural history of unrepaired/partial AVSD and on long-term neurodevelopmental and phenotype-stratified QoL outcomes.
6. Penetrance/expressivity quantification for individual susceptibility variants (e.g., CRELD1) is incomplete.

Proposed Follow-up Experiments / Actions

1. Large-scale trio whole-genome sequencing of non-syndromic AVSD to capture regulatory/non-coding and structural variants and resolve the "missing 40%," with statistical modeling of oligogenic burden.
2. Single-cell / spatial transcriptomics of the developing human AV canal (and iPSC-derived pre-valvular endocardial cells) to map cell-type-specific EndoMT programs and how CRELD1/NFATC1/HMGN1 perturbations reprogram them.
3. Dissect chr21 dosage with combinatorial CRISPR titration of HMGN1, DSCAM, COL6A2 (and modifiers Creld1, Hey2) on trisomic backgrounds to define the defect threshold and rank causal drivers.
4. Prospective AVSD-specific gene–environment study quantifying interaction between maternal glycemic control/folate status and fetal genotype on AVSD risk and severity.
5. Develop predictive tools for LAVV regurgitation — integrate 3D-echo valve morphometry (Rastelli type, leaflet geometry) with clinical/genetic data to guide repair technique and surveillance.
6. Improve prenatal detection through validation and deployment of AI-assisted four-chamber-view screening (AVLR, FINE/STIC) in general obstetric settings, paired with reflex CMA/exome workflows.
7. Optimize periconceptional prevention by testing structured maternal diabetes-control and folate-supplementation programs, and by educating healthcare providers on folate's cardiac benefits.

Report compiled from 22 confirmed findings, 5 supported hypotheses, and 92 reviewed papers across 10 investigation iterations. Evidence sources: human clinical cohorts, population registries, model organisms (mouse, zebrafish, hamster, chick), and in vitro iPSC systems.

Artifacts

• OpenScientist final report
• OpenScientist final report

Citations

1. PMID:29549339
2. PMID:37612667
3. PMID:39104126
4. PMID:37667895
5. PMID:15096951
6. PMID:30007050
7. PMID:24697899
8. PMID:22072978
9. PMID:41125893
10. PMID:23061687
11. PMID:32092068
12. PMID:1943197
13. PMID:10812553
14. PMID:37240614
15. PMID:34196822
16. PMID:33142350
17. PMID:40154545
18. PMID:34002204
19. PMID:8347012
20. PMID:19760623
21. PMID:25328912
22. PMID:25996639
23. PMID:33179873
24. PMID:22523272
25. PMID:33876578
26. PMID:9532811
27. PMID:34953470
28. PMID:42037320
29. PMID:36816019
30. PMID:34627233
31. PMID:26472242
32. PMID:28172500
33. PMID:27056911
34. PMID:39528804
35. PMID:26893350
36. PMID:32655758
37. PMID:31028265
38. PMID:39892564
39. PMID:10946038
40. PMID:42079968
41. PMID:38277408
42. PMID:38975735
43. PMID:30814609
44. PMID:7997413
45. PMID:36766561
46. PMID:27981284
47. PMID:38323184
48. PMID:29952356
49. PMID:34993374
50. PMID:28603940
51. PMID:41877065
52. PMID:41971883
53. PMID:40208292
54. PMID:39233212
55. PMID:41764019
56. PMID:41313357
57. PMID:34350818
58. PMID:39578279
59. PMID:2116616
60. PMID:37794522
61. PMID:40936386
62. PMID:41041190
63. PMID:31131945
64. PMID:33482816
65. PMID:15906378
66. PMID:9231034